As one of the main important research platforms of the Zhejiang-California International Nanosystems Insitute (ZCNI), Systems Biology Platform was founded in May, 2006. ZCNI is a first of its kind research and technology innovation platform in China, which is the international the joint effort among Zhejiang Provincial Government, Zhejiang University (ZJU), California NanoSystems Institute (CNSI), and whose mission is to accelerate the application of nanotechnology in biology, medicine, material, information technology, chemistry etc.
The Systems Biology Platform is mainly focused on 1) Systems Biology and Drug discovery of Cancer; 2) Biomarkers for Cancer; 3) Nano-diagnosis for cancer; 4) Cancer genomics; 5) Personnel genome, which operates as five research groups according to the different major focus, which are genomics based group，Function Verification group, Nano-medicine group, Proteomic group, Nano-image group, Bioinformatics group.
Under the guidance of Prof. Biaoyang Lin, who serves as the director of the platform since 2006, the Systems Biology Systems has been successfully undertaking several national and provincial grants such as two State 863 programs, one State international key collaboration project, two State international key collaboration projects and so on. Over ten papers have been published in peer-reviewed journals, one software copyright has been obtained and a further 4 are Patent Pending.
At present, the Platform is equipped with state-of-the-art equipments (LTQ Orbitrap, Illumina’s 1G Genetic Analyzer, LCM, cell sorter, 32 node computer clusters etc.) and a team consists of computer scientists, chemists, mathematicians, physicists and biologists. The lab is applying Solexa/Illumina’s SBS sequencing technology to understand changes in cancer genomes for common cancers in China such as liver, stomach and colon cancer.